Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 1;6(5):1172-81.
doi: 10.1177/193229681200600522.

GlucoMen Day continuous glucose monitoring system: a screening for enzymatic and electrochemical interferents

Fausto Lucarelli  1 , Francesco Ricci, Felice Caprio, Francesco Valgimigli, Cosimo Scuffi, Danila Moscone, Giuseppe Palleschi
Affiliations

GlucoMen Day continuous glucose monitoring system: a screening for enzymatic and electrochemical interferents

Fausto Lucarelli et al. J Diabetes Sci Technol. .

Abstract

Background: While most of the common drugs with the potential to interfere with continuous glucose monitoring (CGM) systems are accessible over the counter and can be assumed by CGM patients without medical supervision, many other chemicals are frequently used to treat critically ill patients. Continuous glucose monitoring reading accuracy may also be compromised in patients characterized by abnormally high concentrations of physiological interferents. In this article, 22 species selected from endogenous and exogenous chemicals were screened as possible interferents of GlucoMen®Day (GMD), the new microdialysis-based CGM system from A. Menarini Diagnostics.

Method: Interference testing was performed according to the EP7-A2 guideline (Clinical and Laboratory Standards Institute 2005). Interference was evaluated at two levels of glucose, with each interferent additionally tested at two concentrations. Furthermore, two configurations of the GMD disposable sensor kit--one designed for subcutaneous application, the other for direct intravascular CGM--were challenged with interferent-spiked serum and blood samples, respectively.

Results: With the exception of dopamine (however, at very high, nonphysiological concentrations), no interference was observed for all the tested substances. Interestingly, none of the common electrochemical interferents (including ascorbic acid, acetaminophen, and salicylic acid, which represent the major specificity issue for the competing CGM systems) significantly affected the system's output.

Conclusions: These results provide clear insights into the advantages offered by the use of a microdialysis-based CGM system that additionally relies on the detection of hydrogen peroxide at low operating potential. GlucoMen Day may become the CGM system of choice for those patients who require either regular administration of drugs or their glycemia to be tightly controlled in the intensive care unit or similar environments.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The (A) GMD system and disposable sensor kits for (B) interstitial fluid and (C) intravascular application.
Figure 2
Figure 2
GlucoMen Day disposable sensor kits for interstitial fluid application: analysis of interferent-spiked serum samples (n = 3). Test concentrations as reported in Table 2.
Figure 3
Figure 3
GlucoMen Day disposable sensor kits for intravascular application: analysis of interferent-spiked blood samples (n = 3). Test concentrations as reported in Table 2.
Figure 4
Figure 4
GlucoMen Day disposable sensor kits for intravascular application (analysis of interferent-spiked blood samples): raw current profile.
See this image and copyright information in PMC

Comment in

References

    1. Wang J. Electrochemical glucose biosensors. Chem Rev. 2008;108(2):814–825. - PubMed
    1. McGarraugh G. The chemistry of commercial continuous glucose monitors. Diabetes Technol Ther. 2009;11(Suppl 1):S17–24. - PubMed
    1. Feldman B, Brazg R, Schwartz S, Weinstein R. A continuous glucose sensor based on wired enzyme technology — results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther. 2003;5(5):769–779. - PubMed
    1. Cunningham DD, Stenken JA. In vivo glucose sensing. Hoboken: John Wiley & Sons; 2010.
    1. De Block C, Manuel-y-Keenoy B, Van Gaal L, Rogiers P. Intensive insulin therapy in the intensive care unit: assessment by continuous glucose monitoring. Diabetes Care. 2006;29(8):1750–1756. - PubMed

Publication types

MeSH terms